PARP1 and acute myeloid leukemia: A phase I clinical trial data have shown a tolerable response produced by talazoparib (a PARP inhibitor), with decitabine, a DNA methyltransferase inhibitor when used against relapsed/refractory AML (Baer et al., 2022).